The potential for liquid biopsies in the precision medical treatment of breast cancer

Currently the clinical management of breast cancer relies on relatively few prognostic/predictive clinical markers (estrogen receptor, progesterone receptor, HER2), based on primary tumor biology. Circulating biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) may enh...

Descripción completa

Detalles Bibliográficos
Autores principales: Forte, Victoria A., Barrak, Dany K., Elhodaky, Mostafa, Tung, Lily, Snow, Anson, Lang, Julie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850125/
https://www.ncbi.nlm.nih.gov/pubmed/27144060
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0007
_version_ 1782429619879673856
author Forte, Victoria A.
Barrak, Dany K.
Elhodaky, Mostafa
Tung, Lily
Snow, Anson
Lang, Julie E.
author_facet Forte, Victoria A.
Barrak, Dany K.
Elhodaky, Mostafa
Tung, Lily
Snow, Anson
Lang, Julie E.
author_sort Forte, Victoria A.
collection PubMed
description Currently the clinical management of breast cancer relies on relatively few prognostic/predictive clinical markers (estrogen receptor, progesterone receptor, HER2), based on primary tumor biology. Circulating biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) may enhance our treatment options by focusing on the very cells that are the direct precursors of distant metastatic disease, and probably inherently different than the primary tumor's biology. To shift the current clinical paradigm, assessing tumor biology in real time by molecularly profiling CTCs or ctDNA may serve to discover therapeutic targets, detect minimal residual disease and predict response to treatment. This review serves to elucidate the detection, characterization, and clinical application of CTCs and ctDNA with the goal of precision treatment of breast cancer.
format Online
Article
Text
id pubmed-4850125
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-48501252016-05-03 The potential for liquid biopsies in the precision medical treatment of breast cancer Forte, Victoria A. Barrak, Dany K. Elhodaky, Mostafa Tung, Lily Snow, Anson Lang, Julie E. Cancer Biol Med Review Currently the clinical management of breast cancer relies on relatively few prognostic/predictive clinical markers (estrogen receptor, progesterone receptor, HER2), based on primary tumor biology. Circulating biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) may enhance our treatment options by focusing on the very cells that are the direct precursors of distant metastatic disease, and probably inherently different than the primary tumor's biology. To shift the current clinical paradigm, assessing tumor biology in real time by molecularly profiling CTCs or ctDNA may serve to discover therapeutic targets, detect minimal residual disease and predict response to treatment. This review serves to elucidate the detection, characterization, and clinical application of CTCs and ctDNA with the goal of precision treatment of breast cancer. Chinese Anti-Cancer Association 2016-03 /pmc/articles/PMC4850125/ /pubmed/27144060 http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0007 Text en Copyright 2016 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Review
Forte, Victoria A.
Barrak, Dany K.
Elhodaky, Mostafa
Tung, Lily
Snow, Anson
Lang, Julie E.
The potential for liquid biopsies in the precision medical treatment of breast cancer
title The potential for liquid biopsies in the precision medical treatment of breast cancer
title_full The potential for liquid biopsies in the precision medical treatment of breast cancer
title_fullStr The potential for liquid biopsies in the precision medical treatment of breast cancer
title_full_unstemmed The potential for liquid biopsies in the precision medical treatment of breast cancer
title_short The potential for liquid biopsies in the precision medical treatment of breast cancer
title_sort potential for liquid biopsies in the precision medical treatment of breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850125/
https://www.ncbi.nlm.nih.gov/pubmed/27144060
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0007
work_keys_str_mv AT fortevictoriaa thepotentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT barrakdanyk thepotentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT elhodakymostafa thepotentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT tunglily thepotentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT snowanson thepotentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT langjuliee thepotentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT fortevictoriaa potentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT barrakdanyk potentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT elhodakymostafa potentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT tunglily potentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT snowanson potentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer
AT langjuliee potentialforliquidbiopsiesintheprecisionmedicaltreatmentofbreastcancer

Ejemplares similares